Skip to main content

Advertisement

SpringerLink
Log in

Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

Icotinib is the first oral epidermal growth factor receptor (EGFR) tyrosine kinase receptor inhibitor, which has been proven to exert significant inhibitory effects on non-small cell lung cancer in vitro. Clinical evidence has showed that the efficacy of Icotinib on retreating advanced non-small cell lung cancer is comparable to Gefitinib. However, different phenotypes of EGFR can affect the therapeutic outcomes of EGFR tyrosine kinase receptor inhibitor. Therefore, our study focused on efficacy and safety of Icotinib in patients with advanced non-small cell lung cancer of different EGPR phenotypes. Clinical data of patients with advanced non-small cell lung cancer who received Icotinib treatment from August, 2011 to May, 2013 were retrospectively analyzed. Kaplan–Meier analysis was used for survival analysis and comparison. 18 wild-type EGFR and 51 mutant type were found in a total of 69 patients. Objective response rate of patients with mutant type EGFR was 54.9 % and disease control rate was 86.3 %. Objective response rate of wild-type patients was 11.1 % (P = 0.0013 vs mutant type), disease control rate was 50.0 % (P = 0.0017). Median progression-free survival (PFS) of mutant type and wild-type patients were 9.7 and 2.6 months, respectively (P < 0.001). Median PFS of exon 19 mutated mutant patients was 11.3 months, mean PFS of exon 21 L858R mutated mutant patients was 8.7 months (P = 0.3145). Median overall survival (OS) of EGFR mutated patients had not reached. OS time of 13 wild-type patients was 12.9 months (P < 0.001). The common adverse reactions of Icotinib included rash, diarrhea, itching skin with occurrence rates of 24.6 % (17/69), 13.0 % (9/69), and 11.6 % (8/69), respectively. Most adverse reactions were grade I–II. Icotinib has great efficacy in EGFR mutated patients, making it an optimal regimen to treat EGFR mutated patients. Furthermore, most of adverse reactions associated with Icotinib treatment were tolerable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Aberle, D. R., & Brown, K. (2008). Lung cancer screening with CT. Clinics in Chest Medicine, 29(1), 1–14.

    Article  PubMed  Google Scholar 

  2. Hua, X., Ward, K. C., Gillespie, T. W., Lipscomb, J., & Goodman, M. (2013). Non-small cell lung cancer treatment receipt and survival among African–Americans and whites in a rural area. Journal of Community Health, 2013, 1–10.

    Google Scholar 

  3. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine, 346(2), 92–98.

    Article  CAS  PubMed  Google Scholar 

  4. Robert, C., Soria, J. C., Spatz, A., Le Cesne, A., Malka, D., Pautier, P., et al. (2005). Cutaneous side-effects of kinase inhibitors and blocking antibodies. The lancet Oncology, 6(7), 491–500.

    Article  CAS  PubMed  Google Scholar 

  5. Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., et al. (2013). EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. International Journal of Medical Sciences, 10(3), 320–330.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Lee, C. K., Brown, C., Gralla, R. J., Hirsh, V., Thongprasert, S., Tsai, C. M., et al. (2013). Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the National Cancer Institute, 105(9), 595–605.

    Article  CAS  PubMed  Google Scholar 

  7. Iivanainen, E., Lauttia, S., Zhang, N., Tvorogov, D., Kulmala, J., Grenman, R., et al. (2009). The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels. Microvascular Research, 78(3), 278–285.

    Article  CAS  PubMed  Google Scholar 

  8. Dongiovanni, D., Daniele, L., Barone, C., Dongiovanni, V., Fissore, C., Sapino, A., et al. (2008). Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer, 61(1), 73–81.

    Article  PubMed  Google Scholar 

  9. Chen, L., He, Y., Huang, H., Liao, H., & Wei, W. (2008). Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical Oncology, 25(2), 161–171.

    Article  CAS  PubMed  Google Scholar 

  10. Razis, E., Skarlos, D., Briasoulis, E., Dimopoulos, M., Fountzilas, G., Lambropoulos, S., et al. (2005). Treatment of non-small cell lung cancer with gefitinib (‘Iressa’, ZD1839): the Greek experience with a compassionate-use program. Anti-Cancer Drugs, 16(2), 191–198.

    Article  CAS  PubMed  Google Scholar 

  11. Tan, F., Shen, X., Wang, D., Xie, G., Zhang, X., Ding, L., et al. (2012). Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer, 76(2), 177–182.

    Article  PubMed  Google Scholar 

  12. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 350(21), 2129–2139.

    Article  CAS  PubMed  Google Scholar 

  13. Paez, J. G., Janne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500.

    Article  CAS  PubMed  Google Scholar 

  14. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., et al. (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to Gefitinib and Erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 101(36), 13306–13311.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Gandhi, J., Zhang, J., Xie, Y., Soh, J., Shigematsu, H., Zhang, W., et al. (2009). Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS ONE, 4(2), e4576.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., et al. (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology, 11(2), 121–128.

    Article  CAS  PubMed  Google Scholar 

  17. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Journal of Medicine, 362(25), 2380–2388.

    Article  CAS  PubMed  Google Scholar 

  18. Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, S., Wang, D., et al. (2013). Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. The Lancet Oncology, 14(10), 953–961.

    Article  CAS  PubMed  Google Scholar 

  19. Piperdi, B., & Perez-Soler, R. (2012). Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients. Drugs, 72(Suppl 1), 11–19.

    Article  CAS  PubMed  Google Scholar 

  20. Fiala, O., Pesek, M., Finek, J., Benesova, L., Bortlicek, Z., & Minarik, M. (2013). Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line Erlotinib versus the reverse sequence. Anticancer Research, 33(8), 3397–3402.

    CAS  PubMed  Google Scholar 

  21. Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., et al. (2013). Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. The lancet Oncology, 14(10), 981–988.

    Article  CAS  PubMed  Google Scholar 

  22. Costa, D. B., & Kobayashi, S. (2007). Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different? British Journal of Cancer, 96(2), 399.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Wu, J. Y., Yu, C. J., Yang, C. H., Wu, S. G., Chiu, Y. H., Gow, C. H., et al. (2008). First- or second-line therapy with Gefitinib produces equal survival in non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 178(8), 847–853.

    Article  CAS  PubMed  Google Scholar 

  24. Ruppert, A. M., Beau-Faller, M., Neuville, A., Guerin, E., Voegeli, A. C., Mennecier, B., et al. (2009). EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. The European Respiratory Journal, 33(2), 436–440.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was funded by grants from Public Welfare Project of Zhejiang Province (No. 2012C23074), Natural Science Foud of Zhejiang Province (No. Y2110167), and Medical Foud of Zhejiang Province (No. 2008B067).

Author information

Authors and Affiliations

  1. Gerontology Center, The First Affiliated Hospital, Zhejiang University, No. 79, Qingchun Road, Hangzhou, 310003, Zhejiang, China

    Huiyun Pan, Rong Liu, Shengjie Li, Hui Fang & Ziwei Wang

  2. Respiratory Department, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, Zhejiang, China

    Sheng Huang

  3. Respiratory Department, The First Affiliated Hospital, Zhejiang University, No. 79, Qingchun Road, Hangzhou, 310003, Zhejiang, China

    Jianying Zhou

Authors
  1. Huiyun Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shengjie Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ziwei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sheng Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianying Zhou.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pan, H., Liu, R., Li, S. et al. Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes. Cell Biochem Biophys 70, 553–558 (2014). https://doi.org/10.1007/s12013-014-9955-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-9955-y

Keywords

Search

Navigation